Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) EBT Margin (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed EBT Margin for 6 consecutive years, with 784.7% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin changed N/A to 784.7% in Q4 2025 year-over-year; TTM through Dec 2025 was 1795.53%, a 157933.0% increase, with the full-year FY2025 number at 1795.53%, up 157933.0% from a year prior.
  • EBT Margin was 784.7% for Q4 2025 at Relay Therapeutics, up from 10301.62% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 8349600.0% in Q4 2023 to a low of 82765.55% in Q2 2023.
  • A 5-year average of 504787.61% and a median of 11099.31% in 2021 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: crashed -73069408bps in 2021, then skyrocketed 837627154bps in 2023.
  • Relay Therapeutics' EBT Margin stood at 11897.0% in 2021, then crashed by -124bps to 26671.54% in 2022, then surged by 31405bps to 8349600.0% in 2023, then crashed by -100bps to 813.55% in 2024, then rose by 4bps to 784.7% in 2025.
  • Per Business Quant, the three most recent readings for RLAY's EBT Margin are 784.7% (Q4 2025), 10301.62% (Q2 2025), and 1003.46% (Q1 2025).